Actively Recruiting
Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder
Led by Icahn School of Medicine at Mount Sinai · Updated on 2026-03-03
120
Participants Needed
1
Research Sites
205 weeks
Total Duration
On this page
Sponsors
I
Icahn School of Medicine at Mount Sinai
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The researchers will test whether cognitively enhanced transcranial direct current stimulation (tDCS) of the dorsolateral prefrontal cortex can reduce craving in inpatients with cocaine use disorder. Neuroimaging before and after stimulation will establish the neural correlates of recovery and allow predictions of outcomes, which will be assessed throughout the study and one month after its completion. Results could pave the way towards development of a new self-administered intervention to reduce craving when it is needed the most, enhancing recovery real-time and in the natural environment in people with cocaine addiction as generalizable to other drugs of abuse and other disorders of self-control.
CONDITIONS
Official Title
Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to understand and give informed consent
- Men and women 18-60 years of age
- For women of childbearing potential, current use of a medically acceptable form of birth control
- DSM-5 diagnosis of stimulant use disorder with crack/cocaine as the drug of choice
You will not qualify if you...
- Lifetime diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, bipolar I disorder, or delusional disorder as confirmed by the MINI or autism spectrum disorder as confirmed by medical history at the screening visit
- Current clinically significant or unstable medical conditions, including metabolic, endocrinological, oncological or autoimmune diseases, infectious diseases common in people with substance use disorders including Hepatitis B and C or HIV/AIDS
- Use of medications deemed exclusionary by the study team
- Any laboratory value outside the reference range that the senior investigator team considers to be of clinical relevance
- Head trauma with loss of consciousness (>30 min)
- History of neurological or developmental disease of central origin including stroke, brain tumor or seizures
- Metal implants or devices that may be impacted by the electrical stimulation and additional MR contraindications
- Women of childbearing potential must use a medically acceptable birth control method during the study and will be asked to take a pregnancy urine test before exposure to tDCS (or MRI)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10029
Actively Recruiting
Research Team
K
Kathryn Rachel Drury Clinical Research Coordinator
CONTACT
M
Maggie Boros Clinical Research Coordinator
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here